Novo Nordisk’s product plant in Kalundborg, Denmark – already the largest insulin manufacturing site in the world – is set for further expansion.
The Danish diabetes specialist is investing DKK 400m (around €54m) to enlarge the site on the northwestern coast of Zealand by 500m2.
Michael Hallgren, senior vice president and head of production in Kalundborg, said: “The expansion of our production plant highlights our ambition to continue strengthening our presence in Kalundborg.
“The new facilities will give us greater flexibility and enable the installation of equipment that will enhance efficiency and increase the long-term production capacity of the plant.”
The site, which employs some 3,400 people, is a cornerstone of Novo’s global production and produces 50% of the world’s insulin as well as a range of biopharmaceutical products.
The investment in the plant comes just over a month after Novo won unanimous backing from FDA advisors for the approval of IDeglira, its once-daily, fixed-dose combination Tresiba (insulin degludec) and Victoza (liraglutide).
A groundbreaking for the Kalundborg plant’s extension will take place today and work is expected to be completed by the end of 2018.